Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
LINKER-MM1 long-term f/u show ORR 71% (≥CR 52%), median DOR and OS 29.4 and 31.4 months, PFS NR, MRD- (10-5) in 94% of evaluable patients with ≥CR; TEAEs = CRS (46%; G3 1%; most in step-up), neutropenia (44%; G≥3 43%), infxns in 75%.”
Title: Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Authors: Hans C. Lee, Jeffrey A. Zonder, Madhav V. Dhodapkar, Sundar Jagannath, James E. Hoffman, Attaya Suvannasankha, Mansi R. Shah, Suzanne Lentzsch, Rachid Baz, Joseph J. Maly, Swathi Namburi, Matthew J. Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez-Lopez, Michelle DeVeaux, Tito Roccia, Dhruti Chokshi, Megan Seraphin, Kate Knorr, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Naresh Bumma, and Joshua Richter.
You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.
You can find more posts featuring Robert Orlowski on OncoDaily.
